Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study

BACKGROUND: New B-domain deleted third generation recombinant factor VIII (FVIII; GreenGene F™, beroctocog alfa) was launched in 2010. We determined safety and efficacy of GreenGene F™ during routine clinical practice in patients with hemophilia A over a period of 12 months. METHODS: From July 2010...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Soon Ki, Yoo, Ki Young, Lee, Kun Soo, Hwang, Taiju, Choi, Yong Mook, Choi, Eun Jin, Park, Sang Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729640/
https://www.ncbi.nlm.nih.gov/pubmed/29215814
http://dx.doi.org/10.3346/jkms.2018.33.e5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729640/
https://www.ncbi.nlm.nih.gov/pubmed/29215814
http://dx.doi.org/10.3346/jkms.2018.33.e5

Ejemplares similares